MDWD Stock Overview
A biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally.
Snowflake Score | |
---|---|
Valuation | 1/6 |
Future Growth | 2/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
MediWound Ltd. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$19.23 |
52 Week High | US$24.00 |
52 Week Low | US$7.10 |
Beta | 0.82 |
11 Month Change | 23.59% |
3 Month Change | 3.11% |
1 Year Change | 106.33% |
33 Year Change | -27.32% |
5 Year Change | -12.51% |
Change since IPO | -84.09% |
Recent News & Updates
Market Participants Recognise MediWound Ltd.'s (NASDAQ:MDWD) Revenues Pushing Shares 43% Higher
Jul 23Analysts Have Made A Financial Statement On MediWound Ltd.'s (NASDAQ:MDWD) First-Quarter Report
Jun 01Recent updates
Market Participants Recognise MediWound Ltd.'s (NASDAQ:MDWD) Revenues Pushing Shares 43% Higher
Jul 23Analysts Have Made A Financial Statement On MediWound Ltd.'s (NASDAQ:MDWD) First-Quarter Report
Jun 01Revenues Tell The Story For MediWound Ltd. (NASDAQ:MDWD) As Its Stock Soars 25%
May 07We're Hopeful That MediWound (NASDAQ:MDWD) Will Use Its Cash Wisely
Feb 28Optimistic Investors Push MediWound Ltd. (NASDAQ:MDWD) Shares Up 26% But Growth Is Lacking
Feb 01MediWound Ltd.'s (NASDAQ:MDWD) 26% Share Price Surge Not Quite Adding Up
Dec 18MediWound Ltd. (NASDAQ:MDWD) Stock Rockets 28% As Investors Are Less Pessimistic Than Expected
Sep 29MediWound's NexoBrid for thermal burns in children gets EMA review
Sep 20Need To Know: Analysts Just Made A Substantial Cut To Their MediWound Ltd. (NASDAQ:MDWD) Estimates
Aug 11MediWound GAAP EPS of -$0.13 misses by $0.03, revenue of $4.67M misses by $0.61M
Aug 09MediWound refiling for NexoBrid to treat severe thermal burns gets FDA review
Aug 03MediWound adds 13% after favorable data for ulcer candidate
Jul 07MediWound taps Tzvi Palash as COO
Jun 30Is MediWound (NASDAQ:MDWD) In A Good Position To Deliver On Growth Plans?
Jun 24Here's Why We're Watching MediWound's (NASDAQ:MDWD) Cash Burn Situation
Dec 07MediWound: Adjusting My Strategy After NexoBrid CRL
Jul 28MediWound completes enrollment for interim assessment of mid-stage EscharEx study
Jun 09MediWound EPS beats by $0.02, beats on revenue
May 05We're Hopeful That MediWound (NASDAQ:MDWD) Will Use Its Cash Wisely
May 04MediWound: Managing A Position Ahead Of NexoBrid's PDUFA
May 02Shareholder Returns
MDWD | US Pharmaceuticals | US Market | |
---|---|---|---|
7D | -0.7% | -2.2% | 2.1% |
1Y | 106.3% | 16.5% | 20.5% |
Return vs Industry: MDWD exceeded the US Pharmaceuticals industry which returned 17.1% over the past year.
Return vs Market: MDWD exceeded the US Market which returned 16.9% over the past year.
Price Volatility
MDWD volatility | |
---|---|
MDWD Average Weekly Movement | 13.1% |
Pharmaceuticals Industry Average Movement | 9.7% |
Market Average Movement | 6.0% |
10% most volatile stocks in US Market | 14.6% |
10% least volatile stocks in US Market | 3.0% |
Stable Share Price: MDWD's share price has been volatile over the past 3 months.
Volatility Over Time: MDWD's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2000 | 100 | Ofer Gonen | www.mediwound.com |
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; and MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma.
MediWound Ltd. Fundamentals Summary
MDWD fundamental statistics | |
---|---|
Market cap | US$178.52m |
Earnings (TTM) | -US$12.75m |
Revenue (TTM) | US$19.85m |
9.0x
P/S Ratio-14.0x
P/E RatioIs MDWD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
MDWD income statement (TTM) | |
---|---|
Revenue | US$19.85m |
Cost of Revenue | US$16.49m |
Gross Profit | US$3.36m |
Other Expenses | US$16.11m |
Earnings | -US$12.75m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -1.37 |
Gross Margin | 16.92% |
Net Profit Margin | -64.24% |
Debt/Equity Ratio | 0% |
How did MDWD perform over the long term?
See historical performance and comparison